TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02449707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Window Technique Augmentation for Maxillary Sinus
Description: Maxillary sinus augmentation will be performed using the lateral window technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Window Technique Augmentation for Maxillary Sinus
Description: Maxillary sinus augmentation will be performed using the lateral window technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound activated resorbable poly-D-L-lactide pins
Description: The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Purus® Cancellous Allograft
Description: Allograft material placed in the sinus to acheive sinus augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purus® Cancellous Allograft
Description: Allograft material placed in the sinus to acheive sinus augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resorb X Membrane
Description: The membrane placed over the graft material before placement of the ultrasound activated pins

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomend
Description: Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cone Beam CT image of the Sinus
Description: Cone beam CT will used to assess the thickness of bone formation after the placement of the graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone Beam CT image of the Sinus
Description: Cone beam CT will used to assess the thickness of bone formation after the placement of the graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trephine Biopsy
Description: Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trephine Biopsy
Description: Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
Study: NCT01278849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Study: NCT00928083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 50mg API capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 200mg API capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 800mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 800mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 800mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 800mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 100mg API capsules
Description: OZ439 100mg (2x50mg API capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg API capsules
Description: OZ439 400mg (2x200mg API capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg API capsules
Description: OZ439 400mg (2x200mg API capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 1600mg aqueous dispersion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 800mg API capsules
Description: OZ439 800mg (4x200 API capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 1200mg API capsules
Description: OZ439 1200mg (6x200mg API capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 200mg aqueous dispersion
Study: NCT03503448

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Osteotomy between the maxillary central incisors
Description: Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Osteotomy between the maxillary lateral incisors and canines
Description: Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
Study: NCT01830569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EBMeDS system
Description: The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group.

Intervention type: OTHER
Group type: OTHER
Intervention: Evidence Linker
Description: The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence Linker
Description: The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
Study: NCT02924480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cystectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive lidocaine infusion during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive saline infusion during surgery
Study: NCT05478226

Intervention type: OTHER
Intervention: drugs or BPA
Description: PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat

Intervention type: OTHER
Intervention: drugs or BPA
Description: PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat

Intervention type: OTHER
Intervention: drugs or BPA
Description: PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
Study: NCT02116049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure Intervention
Description: The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Case Management
Description: Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
Study: NCT01365429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPS™ with Steen Solution™
Description: The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
Study: NCT02388763

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized
Study: NCT01052090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHN121
Description: a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
Study: NCT03876561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor prehabilitation
Description: The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
Study: NCT03451201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Continuous Exercise Training
Description: Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity

Intervention type: OTHER
Group type: OTHER
Intervention: Non-exercise
Description: Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
Study: NCT02170688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight calculation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight calculation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight calculation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight calculation
Study: NCT02079532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: 1 g was given by intravenous infusion on Days 1 and 15
Study: NCT01471366

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Frozen capsule
Description: Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule with food
Description: Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule without food
Description: Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule with milk
Description: Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
Study: NCT04641559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutrition group
Description: A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Plan group
Description: Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
Study: NCT01117610

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (one of medication)
Description: patients in Group C will receive none of medication preoperatively and intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (epidural injection)
Description: patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
Study: NCT01210001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching BI 10773 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily
Study: NCT04287426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Description: Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 2 µg/kg
Description: Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
Study: NCT00825227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil 150 mg/day
Description: * 150 mg/day armodafinil~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,
Description: * placebo~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents
Study: NCT02494765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel TM
Description: Airway management with I-gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraOnce (AO)
Description: Airway management with Ambu AuraOnce (AO)
Study: NCT02333370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Study: NCT00577668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Velcade, Thalidomide, Dexamethasone
Description: To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
Study: NCT02162069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE certified transcatheter ( aortic valve replacement)
Description: Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
Study: NCT04420923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observe and Plan
Description: First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treat-and-Extend
Description: At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks.
Study: NCT03064022

Intervention type: OTHER
Intervention: Growth
Description: Some preterm infants grow at higher rates than others
Study: NCT03066453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobi Inhalant Product
Description: inhaled tobramycin 300 mg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobi Inhalant Product
Description: inhaled tobramycin 300 mg twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebcin
Description: 10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebcin
Description: 10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
Study: NCT02253979

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard double lumen tube
Description: Endotracheal left side double lumen tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight double lumen tube
Description: VivaSight double lumen endotracheal intubation
Study: NCT00584311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and Ultrasound
Description: MRI and US of the joint
Study: NCT02272764

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Administered orally in a crossover design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Administered sublingually in a crossover design